GlassScriptPhysician profile
Timothy J Lederer
NPI 1033695960
$5,473.65
in general payments reported to CMS, 2019-2025
44 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.54 · 2022: $25.20 · 2023: $559 · 2024: $2,196 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,361 · Education: $53.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,360.70 |
| Education | $53.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $929.32 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $536.88 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $366.68 | 2023-2025 | |
| Amgen INC. | $336.88 | 2024-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $267.16 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $241.86 | 2024-2025 | Spravato |
| Lundbeck LLC | $231.77 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $221.56 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $208.61 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $195.51 | 2023 | Dupixent |
| Astellas Pharma US INC | $148.54 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $148.41 | 2024-2025 | Eliquis, Camzyos |
| Grifols USA, LLC | $143.83 | 2024-2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $125.93 | 2024-2025 | Zemaira |
| Exact Sciences Corporation | $123.66 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $102.55 | 2023-2024 | Trelegy Ellipta, Nucala, Shingrix |
| Esperion Therapeutics, INC. | $93.47 | 2024-2025 | Nexletol |
| Neurocrine Biosciences, INC. | $80.87 | 2024-2025 | Ingrezza |
| Corcept Therapeutics | $73.98 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $69.96 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $61.28 | 2024-2025 | Rexulti |
| Dexcom, INC. | $57.41 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.97 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $56.71 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.86 | 2025 | Xifaxan |
| Verona Pharma, INC. | $50.90 | 2025 | Ohtuvayre |
| Sumitomo Pharma America, INC. | $47.49 | 2025 | Gemtesa |
| Abbott Laboratories | $47.22 | 2024-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $46.57 | 2023 | Xolair |
| Genzyme Corporation | $41.06 | 2023 | |
| Baxter Healthcare | $34.81 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Harmony Biosciences LLC | $28.64 | 2024 | |
| Optinose US, INC. | $25.38 | 2025 | |
| Currax Pharmaceuticals LLC | $24.57 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $23.81 | 2023 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $23.57 | 2024 | Trintellix |
| Kaleo, INC. | $21.10 | 2023 | Auvi-Q |
| Alkermes, INC. | $20.94 | 2024 | Lybalvi |
| Phathom Pharmaceuticals, INC. | $19.26 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $18.79 | 2025 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.60 | 2024 | Caplyta |
| Electronic Waveform Lab, INC. | $18.14 | 2023 | |
| Axsome Therapeutics, INC. | $17.43 | 2025 | Auvelity |
| Globus Medical, INC. | $13.71 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lederer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.